对于患有严重血友病A的儿童,Efanesoctocog Alfa预防
Lynn Malec1, Flora Peyvandi1, Anthony K C Chan1
1From Versiti Blood Research Institute, and the Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin - both in Milwaukee (L.M.); IRCCS Ca' Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, and Università degli Studi di Milano, Department of Pathophysiology and Transplantation - both in Milan (F.P.); McMaster Children's Hospital, McMaster University, Hamilton, ON (A.K.C.C.), and the Division of Hematology-Oncology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto (M.C.) - both in Canada; Goethe University Frankfurt, University Hospital, Department of Pediatrics and Adolescent Medicine, Frankfurt, Germany (C.K.); the Department of Pediatric Hematology, Istanbul University Oncology Institute, Inherited Bleeding Disorders, Istanbul, Turkey (B.Z.); Sanofi, Cambridge, MA (H.Y., M.D.); Rush University Medical Center, Rush Hemophilia and Thrombophilia Center, Chicago (M.S.); Hospital Universitario La Paz, Autonoma University of Madrid, IdiPAZ, Madrid (M.T.Á.R.); University of Iowa Stead Family Children's Hospital, Carver College of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Oncology, and Bone Marrow Transplant, Iowa City (J.M.S.); the Division of Hematology, Oncology, and Blood and Marrow Transplant at Nationwide Children's Hospital and the Ohio State University College of Medicine, Columbus (A.L.D.); the Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan (S.-C.C.); Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles and Hémostase Inflammation Thrombose, Unité Mixte de Recherche S1176, INSERM, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, France (R.O.); University Children's Hospital, Zurich (M.A.), and Sobi, Basel (E.S., L.A.-F.) - both in Switzerland; Sanofi, Bridgewater, NJ (A.Y., N.W., S.G.); and Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam (K.F.).
每周一次的efanesoctocog alfa预防有效地预防严重血友病A儿童的出血,保持高的VIII因子活性,并具有良好的安全性.
科学领域:
- 血液学 血液学 血液学
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的血友病 12岁以下儿童的治疗需要有效的预防.
- 有限的数据存在于这个儿科群体中efanesoctocog alfa的结果.
研究的目的:
- 为了评估每周一次的efanesoctocog alfa在以前治疗过的患有严重血友病A的儿童 (<12岁) 的疗效和安全性.
- 评估第八因子抑制剂的发展,出血率和药理动力学.
主要方法:
- 第3期,对74名先前接受过治疗的严重血友病A型男性患者 (<12岁) 的开放性研究.
- 每周一次的efanesoctocog alfa预防 (50 IU/kg) 在52周内.
- 主要终点:第八因子抑制剂的发生;次要终点:出血率,安全性,药理动力学.
主要成果:
- 在任何患者中,都没有出现XVIII因子抑制剂的发展.
- 年平均出血率为0.00;64%的人没有经过治疗的出血发作.
- 剂量后的平均XVIII因子活性在3天内保持在>40 IU/dL,在近7天内保持在>10 IU/dL.
- 大多数不良事件都是不严重的,没有研究者评估的与药物相关的严重不良事件.
结论:
- 每周一次的efanesoctocog alfa在患有严重血友病A的儿童 (<12岁) 中提供持续的第八因子活性,从而实现有效的出血预防.
- 该疗法表现出良好的安全性,主要是不严重的不良事件.


